CHAMPIONS ONCOLOGY, INC. Total Liabilities and Equity
CHAMPIONS ONCOLOGY, INC. (CSBR) had Total Liabilities and Equity of $33.29 million as of 2026-07-31, per its 10-Q filed 2026-09-11.
Financial Statements › Balance Sheet
us-gaap:LiabilitiesAndStockholdersEquity · last filed 2026-09-11
- 2026-07-31: Liabilities and Equity $33.29M.
- 2026-04-30: Liabilities and Equity $26.99M.
- 2026-01-31: Liabilities and Equity $28.45M.
- 2025-10-31: Liabilities and Equity $30.16M.
| Period end | Liabilities and Equity |
|---|---|
| 2026-07-31 | $33.29M 10-Q · filed 2026-09-11 |
| 2026-04-30 | $26.99M 10-Q · filed 2026-09-11 |
| 2026-01-31 | $28.45M 10-Q · filed 2026-03-12 |
| 2025-10-31 | $30.16M 10-Q · filed 2025-12-15 |
| 2025-07-31 | $30.55M 10-Q · filed 2025-09-15 |
| 2025-04-30 | $32.34M 10-K · filed 2026-07-27 |
| 2025-01-31 | $30.63M 10-Q · filed 2025-03-17 |
| 2024-10-31 | $25.24M 10-Q · filed 2024-12-16 |
| 2024-07-31 | $24.93M 10-Q · filed 2024-09-13 |
| 2024-04-30 | $26.13M 10-K · filed 2025-07-23 |
| 2024-01-31 | $26.79M 10-Q · filed 2024-03-15 |
| 2023-10-31 | $28.29M 10-Q · filed 2023-12-13 |
| 2023-07-31 | $29.91M 10-Q · filed 2023-09-13 |
| 2023-04-30 | $34.31M 10-K · filed 2024-07-19 |
| 2023-01-31 | $36.15M 10-Q · filed 2023-03-16 |
| 2022-10-31 | $36.36M 10-Q · filed 2022-12-13 |
| 2022-07-31 | $34.39M 10-Q · filed 2022-09-12 |
| 2022-04-30 | $35.38M 10-K · filed 2023-07-24 |
| 2022-01-31 | $33.58M 10-Q · filed 2022-03-15 |
| 2021-10-31 | $29.30M 10-Q · filed 2021-12-13 |
| 2021-07-31 | $28.11M 10-Q · filed 2021-09-13 |
| 2021-04-30 | $27.59M 10-K · filed 2022-07-22 |
| 2021-01-31 | $25.26M 10-Q · filed 2021-03-15 |
| 2020-10-31 | $25.76M 10-Q · filed 2020-12-14 |
| 2020-07-31 | $22.82M 10-Q · filed 2020-09-14 |
| 2020-04-30 | $20.75M 10-K · filed 2021-07-26 |
| 2020-01-31 | $15.07M 10-Q · filed 2020-03-16 |
| 2019-10-31 | $13.95M 10-Q · filed 2019-12-16 |
| 2019-07-31 | $13.36M 10-Q · filed 2019-09-16 |
| 2019-04-30 | $11.27M 10-K · filed 2020-07-28 |
| 2019-01-31 | $10.91M 10-Q · filed 2019-03-18 |
| 2018-10-31 | $10.24M 10-Q · filed 2018-12-17 |
| 2018-07-31 | $8.39M 10-Q · filed 2018-09-14 |
| 2018-04-30 | $8.08M 10-K · filed 2019-07-29 |
| 2018-01-31 | $7.09M 10-Q · filed 2018-03-19 |
| 2017-10-31 | $6.49M 10-Q · filed 2017-12-15 |
| 2017-07-31 | $6.47M 10-Q · filed 2017-09-14 |
| 2017-04-30 | $8.01M 10-K · filed 2018-07-30 |
| 2017-01-31 | $7.55M 10-Q · filed 2017-03-17 |
| 2016-10-31 | $8.04M 10-Q · filed 2016-12-14 |
| 2016-07-31 | $7.85M 10-Q · filed 2016-09-14 |
| 2016-04-30 | $5.78M 10-K · filed 2017-07-28 |
| 2016-01-31 | $7.14M 10-Q · filed 2016-03-16 |
| 2015-10-31 | $7.58M 10-Q · filed 2015-12-15 |
| 2015-07-31 | $9.85M 10-Q · filed 2015-09-11 |
| 2015-04-30 | $12.05M 10-K · filed 2016-07-29 |
| 2015-01-31 | $2.83M 10-Q · filed 2015-03-17 |
| 2014-10-31 | $3.31M 10-Q · filed 2014-12-15 |
| 2014-07-31 | $5.68M 10-Q · filed 2014-09-12 |
| 2014-04-30 | $8.87M 10-K · filed 2015-07-29 |
| 2014-01-31 | $10.47M 10-Q · filed 2014-03-14 |
| 2013-10-31 | $10.50M 10-Q · filed 2013-12-13 |
| 2013-07-31 | $10.67M 10-Q · filed 2013-09-13 |
| 2013-04-30 | $11.65M 10-K · filed 2014-07-28 |
| 2013-01-31 | $13.01M 10-Q · filed 2013-03-13 |
| 2012-10-31 | $4.22M 10-Q · filed 2012-12-13 |
| 2012-07-31 | $5.14M 10-Q · filed 2012-09-12 |
| 2012-04-30 | $6.92M 10-K · filed 2013-07-26 |
| 2012-01-31 | $8.87M 10-Q · filed 2012-03-14 |
| 2011-10-31 | $9.87M 10-Q · filed 2011-12-14 |
| 2011-07-31 | $11.80M 10-Q · filed 2011-09-13 |
| 2011-04-30 | $12.65M 10-K · filed 2012-07-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| EXOZYMES INC. (EXOZ) | United States | $0.058B | |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |